Last reviewed · How we verify
Haloperidol Injection
Haloperidol blocks dopamine D2 receptors in the brain, reducing dopaminergic neurotransmission to treat psychotic symptoms and agitation.
Haloperidol blocks dopamine D2 receptors in the brain, reducing dopaminergic neurotransmission to treat psychotic symptoms and agitation. Used for Acute agitation and psychosis, Schizophrenia, Bipolar disorder (acute mania).
At a glance
| Generic name | Haloperidol Injection |
|---|---|
| Also known as | Magnesium Sulphate, Serenase, haloperidol |
| Sponsor | Hennepin Healthcare Research Institute |
| Drug class | First-generation antipsychotic (typical antipsychotic) |
| Target | Dopamine D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Haloperidol is a first-generation (typical) antipsychotic that antagonizes dopamine D2 receptors, particularly in the mesolimbic and mesocortical pathways. This dopamine blockade reduces positive symptoms of psychosis such as hallucinations and delusions, and also provides sedative and antiemetic effects. The injection formulation allows for rapid onset and is used in acute psychiatric emergencies.
Approved indications
- Acute agitation and psychosis
- Schizophrenia
- Bipolar disorder (acute mania)
- Severe behavioral disturbances
- Delirium
Common side effects
- Extrapyramidal symptoms (dystonia, akathisia, parkinsonism)
- Sedation
- Orthostatic hypotension
- Tardive dyskinesia (chronic use)
- Neuroleptic malignant syndrome
- QT prolongation
Key clinical trials
- A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (PHASE3)
- Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department (PHASE4)
- Combination of Haloperidol and Magnesium for Delirium Prevention in Critically Ill Elderly (PHASE2, PHASE3)
- The IM-ZBULLE Study : " Z-track " and " Airlock " Techniques During Intramuscular Injection of Haloperidol Decanoate (NA)
- A Study of Olanzapine in Patients With Acute Agitation (PHASE3)
- Agents Intervening Against Delirium in Intensive Care Unit (PHASE4)
- IM Olanzapine Versus Haloperidol or Midazolam (PHASE4)
- Haloperidol and Dexamethasone Towards Postoperative Nausea and Pain in Adult After Laparoscopy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Haloperidol Injection CI brief — competitive landscape report
- Haloperidol Injection updates RSS · CI watch RSS
- Hennepin Healthcare Research Institute portfolio CI